10-Q: Lyell Immunopharma Reports Q1 2025 Financial Results, Highlights LYL314 Clinical Progress

Lyell Immunopharma announces its Q1 2025 financial results and provides an update on the clinical development of LYL314, its lead CAR T-cell therapy candidate.

Summary

• Lyell Immunopharma reported a net loss of $52.2 million for the first quarter of 2025, compared to a net loss of $60.7 million for the same period in 2024.
• Research and development expenses were $43.4 million, slightly up from $43.2 million in the prior year.
• General and administrative expenses increased to $14.0 million from $13.5 million.
• The company's cash, cash equivalents, and marketable securities totaled $330.1 million as of March 31, 2025.
• Lyell expects its current cash resources to fund operations into 2027.
• The company is advancing LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy, with a pivotal trial expected to begin in mid-2025.
• Initial data from the Phase 1/2 trial of LYL314 showed a 94% overall response rate and a 71% complete response rate in efficacy-evaluable patients.
• LYL314 has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA.
• Manufacturing of LYL314 has been successfully transferred to Lyell's LyFE Manufacturing Center in Bothell, Washington.
• The company expects to present more mature data from the ongoing Phase 1/2 trial from patients in the second-line setting in late-2025.
• Lyell anticipates initiating a pivotal trial by early 2026 in patients with relapsed and/or refractory LBCL in the second-line setting who have not yet received CAR T-cell therapy.
• The first IND submission for a fully-armed CAR T-cell product candidate with an undisclosed target for solid tumors is expected in 2026.
• The company closed its West Hills manufacturing facility in March 2025, resulting in a workforce reduction of approximately 73 employees.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While the company is still operating at a loss, there are positive indicators such as the decrease in net loss compared to the previous year, promising clinical data for LYL314, and successful transfer of manufacturing to its own facility. The company's financial position appears stable, with sufficient cash to fund operations into 2027. However, there are also risks and challenges associated with the company's novel technologies and competitive landscape.

Positives

• The company's net loss decreased compared to the same period last year.
• The company has a substantial amount of cash and marketable securities on hand.
• LYL314 shows promising clinical data with high response rates.
• LYL314 has received important designations from the FDA, which could expedite its development.
• The company has successfully transferred manufacturing to its own facility, providing greater control over production.
• The company expects its current cash resources to fund operations into 2027.

Negatives

• The company continues to operate at a loss.
• The company is still in the early stages of clinical development.
• The company closed its West Hills manufacturing facility in March 2025, resulting in a workforce reduction of approximately 73 employees.

Risks

• The company's product candidates are based on novel technologies that are unproven and may not result in approvable or marketable products.
• The company faces substantial competition in rapidly changing industries.
• The company is dependent on the enrollment and retention of patients in its current and planned clinical trials.
• The company may be unable to comply with the applicable continued listing requirements of The Nasdaq Global Select Market.
• The company may be unable to successfully integrate ImmPACT into its business, including completing the transition of the manufacturing of LYL314 to its LyFE Manufacturing Center.

Future Outlook

Lyell expects its current cash resources to fund operations into 2027 and anticipates initiating a pivotal trial for LYL314 in mid-2025. The company also expects to present more mature data from the ongoing Phase 1/2 trial in late 2025 and initiate a pivotal trial in the second-line setting by early 2026.

Management Comments

• LYL314 clinical supply is now being manufactured at our LyFE Manufacturing Center TM (LyFE) in Bothell, Washington following successful technology transfer and clearance by the FDA of an Investigational New Drug (IND) amendment.

Industry Context

The company is operating in the competitive field of cell therapy, particularly CAR T-cell therapies for cancer treatment. The report highlights the need for more effective and durable therapies compared to existing CD19-targeted CAR T-cell therapies, which is the focus of Lyell's LYL314 program.

Comparison to Industry Standards

• The median peak expansion of LYL314 is approximately fourfold higher than the median peak expansion reported for lisocabtagene maraleucel, a CD19 CAR T-cell therapy approved for patients with relapsed and/or refractory LBCL.
• Data from the ZUMA-7 pivotal trial of axicabtagene ciloleucel in patients with relapsed and/or refractory large B-cell lymphoma demonstrated an improved overall survival in those patients with a higher median percentage of T cells with a naive/stem memory phenotype in the administered cell product.

Related Party Transactions

• In September 2021, the Company entered into a sublease with Sonoma (Sonoma Sublease), with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, but also potential for increased value if product candidates are successful.
• Employees: Workforce reduction at the West Hills facility, but potential for growth and new opportunities as the company advances its pipeline.
• Patients: Potential for new and improved treatment options for cancer.
• Suppliers: Continued business relationships for manufacturing and research activities.

Next Steps

• Initiate a pivotal trial for LYL314 in mid-2025.
• Present more mature data from the ongoing Phase 1/2 trial in late 2025.
• Initiate a pivotal trial in the second-line setting by early 2026.
• Submit the first IND for a fully-armed CAR T-cell product candidate for solid tumors in 2026.

Key Dates

Keywords

LYL314, CAR T-cell therapy, clinical trial, Immunopharma, RMAT designation, LBCL, manufacturing, financial results, research and development, oncology